Last Updated: November 16, 2026

Investigational Drug Information for AZD4635

« Back to Dashboard


What is the drug development status for AZD4635?

AZD4635 is an investigational drug.

There have been 7 clinical trials for AZD4635. The most recent clinical trial was a Phase 1 trial, which was initiated on August 29th 2019.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neoplasms. The leading clinical trial sponsors are AstraZeneca, Parexel, and MedImmune LLC.

There are one hundred and sixteen US patents protecting this investigational drug and one hundred and forty-nine international patents.

Recent Clinical Trials for AZD4635
TitleSponsorPhase
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.ParexelPhase 2
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.AstraZenecaPhase 2
A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy VolunteersParexelPhase 1

See all AZD4635 clinical trials

Clinical Trial Summary for AZD4635

Top disease conditions for AZD4635
Top clinical trial sponsors for AZD4635

See all AZD4635 clinical trials

US Patents for AZD4635

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD4635 ⤷  Start Trial 1,2,4-triazine-4-amine derivatives Heptares Therapeutics Limited (Welwyn Garden, GB) ⤷  Start Trial
AZD4635 ⤷  Start Trial Microparticle formulations of adenosine receptor antagonists for treating cancer PHOSPHOREX, INC. (Hopkinton, MA) ⤷  Start Trial
AZD4635 ⤷  Start Trial PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Start Trial
AZD4635 ⤷  Start Trial PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD4635

Drugname Country Document Number Estimated Expiration Related US Patent
AZD4635 Australia AU2011212430 2030-02-05 ⤷  Start Trial
AZD4635 Brazil BR112012019540 2030-02-05 ⤷  Start Trial
AZD4635 Canada CA2789279 2030-02-05 ⤷  Start Trial
AZD4635 China CN102822150 2030-02-05 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.